

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/774,176-Conf. #7186 |
| | | | | Filing Date | February 6, 2004 |
| | | | | First Named Inventor | Miles W. Carroll |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | M. DiBrino |
| Sheet | 1 | of | 1 | Attorney Docket Number | 31127/43656C |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|--|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
| | | | | | | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|---|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| /M.D./ | C11 | Bodey et al., "Failure of cancer vaccines: The significant limitations of this approach to immunotherapy," <i>Anticancer Res.</i> , 20:2665-2676, 2000. | |
| ↓ | C12 | Boon, "Towards a genetic analysis of tumor rejection antigens," <i>Adv. Cancer Res.</i> , 58:177-210, 1992. | |
| | C13 | DeGruijl et al., "Cancer vaccine strategies get bigger and better," <i>Nature Med.</i> , 5:1124-1125, 1999. | |
| | C14 | Ezzell, "Cancer 'vaccines': An idea whose time has come?," <i>J. NIH Res.</i> , 7:46-49, 1995. | |
| | C15 | Gaiger et al., "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," <i>Blood</i> , 96:1480-1489, 2000. | |
| | C16 | Oxford BioMedica announces FDA agreement on revisions for ongoing TroVax® phase III TRIST study. News 2008/OB/31, October 07, 2008. | |
| ↓ | C17 | Oxford BioMedica reports data on association between immune response and patient survival from TroVax® trials in colorectal, renal and prostate cancer. News 2008/OB/33, October 24, 2008. | |
| | /M.D./ | C18 | Spitler "Cancer Vaccines: The interferon analogy," <i>Cancer Biother.</i> , 10:1-3, 1995. |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Marianne DiBrino/ | Date Considered | 01/27/2009 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.